The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
Open accessAbstract
BACKGROUND: The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy. METHODS: We analyzed surveillance data on inpatients younger than 21 years of age who had MIS-C and were admitted to 1 of 58 U.S. hospitals between March 15 and October 31, 2020. The effectiveness of initial immunomodulatory therapy (day 0, indicating the first day any such therapy for MIS-C was given) with intravenous immune globulin (IVIG) plus glucocorticoids, as compared with IVIG alone, was evaluated with propensity-score matching and inverse probability weighting, with adjustment for baseline MIS-C severity and demographic characteristics. The primary outcome was cardiovascular dysfunction (a composite of left ventricular dysfunction or shock resulting in the use of vasopressors) on or after day 2. Secondary outcomes included the components of the primary outcome, the receipt of adjunctive treatment (glucocorticoids in patients not already receiving glucocorticoids on day 0, a biologic, or a second dose of IVIG) on or after day 1, and persistent or recurrent fever on or after day 2. RESULTS: A total of 518 patients with MIS-C (median age, 8.7 years) received at least one immunomodulatory therapy; 75% had been previously healthy, and 9 died. In the propensity-score-matched analysis, initial treatment with IVIG plus glucocorticoids (103 patients) was associated with a lower risk of cardiovascular dysfunction on or after day 2 than IVIG alone (103 patients) (17% vs. 31%; risk ratio, 0.56; 95% confidence interval [CI], 0.34 to 0.94). The risks of the components of the composite outcome were also lower among those who received IVIG plus glucocorticoids: left ventricular dysfunction occurred in 8% and 17% of the patients, respectively (risk ratio, 0.46; 95% CI, 0.19 to 1.15), and shock resulting in vasopressor use in 13% and 24% (risk ratio, 0.54; 95% CI, 0.29 to 1.00). The use of adjunctive therapy was lower among patients who received IVIG plus glucocorticoids than among those who received IVIG alone (34% vs. 70%; risk ratio, 0.49; 95% CI, 0.36 to 0.65), but the risk of fever was unaffected (31% and 40%, respectively; risk ratio, 0.78; 95% CI, 0.53 to 1.13). The inverse-probability-weighted analysis confirmed the results of the propensity-score-matched analysis. CONCLUSIONS: Among children and adolescents with MIS-C, initial treatment with IVIG plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. (Funded by the Centers for Disease Control and Prevention.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
McCrindle, B. W., Rowley, A. H., Newburger, J. W., Burns, J. C., Bolger, A. F., Gewitz, M., Baker, A. L., Jackson, M. A., Takahashi, M., Shah, P. B., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000484 · Cited by 3,723
Self-citationMultisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021680 · Cited by 2,643
Self-citationHyperinflammatory shock in children during COVID-19 pandemic
Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N., & Theocharis, P. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31094-1 · Cited by 2,494
Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri, M., Ciuffreda, M., Bonanomi, E., & D'Antiga, L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31103-x · Cited by 2,380
Multisystem Inflammatory Syndrome in Children in New York State
Dufort, E. M., Koumans, E. H., Chow, E. J., Rosenthal, E. M., Muse, A., Rowlands, J., Barranco, M. A., Maxted, A. M., Rosenberg, E. S., Easton, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021756 · Cited by 1,350
Self-citationBelhadjer, Z., Méot, M., Bajolle, F., Khraiche, D., Legendre, A., Abakka, S., Auriau, J., Grimaud, M., Oualha, M., Beghetti, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048360 · Cited by 1,129
Feldstein, L. R., Tenforde, M. W., Friedman, K. G., Newhams, M., Rose, E. B., Dapul, H., Soma, V. L., Maddux, A. B., Mourani, P. M., Bowens, C., et al. (2021) · JAMA · doi:10.1001/jama.2021.2091 · Cited by 817
Self-citationCOVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020
Godfred-Cato, S., Bryant, B., Leung, J., Oster, M. E., Conklin, L., Abrams, J., Roguski, K., Wallace, B., Prezzato, E., Koumans, E. H., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6932e2 · Cited by 769
Kobayashi, T., Saji, T., Otani, T., Takeuchi, K., Nakamura, T., Arakawa, H., Kato, T., Hara, T., Hamaoka, K., Ogawa, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61930-2 · Cited by 676
Swann, O. V., Holden, K. A., Turtle, L., Pollock, L., Fairfield, C. J., Drake, T. M., Seth, S., Egan, C., Hardwick, H. E., Halpin, S., et al. (2020) · BMJ · doi:10.1136/bmj.m3249 · Cited by 643
Recognition of a Kawasaki Disease Shock Syndrome
Kanegaye, J. T., Wilder, M. S., Molkara, D., Frazer, J. R., Pancheri, J., Tremoulet, A. H., Watson, V. E., Best, B. M., & Burns, J. C. (2009) · PEDIATRICS · doi:10.1542/peds.2008-1871 · Cited by 433
Carter, M. J., Fish, M., Jennings, A., Doores, K. J., Wellman, P., Seow, J., Acors, S., Graham, C., Timms, E., Kenny, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1054-6 · Cited by 419
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41616 · Cited by 412
Self-citationMultisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2
Diorio, C., Henrickson, S. E., Vella, L. A., McNerney, K. O., Chase, J., Burudpakdee, C., Lee, J. H., Jasen, C., Balamuth, F., Barrett, D. M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140970 · Cited by 402
Self-citationLee, P. Y., Day-Lewis, M., Henderson, L. A., Friedman, K. G., Lo, J., Roberts, J. E., Lo, M. S., Platt, C. D., Chou, J., Hoyt, K. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141113 · Cited by 396
Self-citationOuldali, N., Toubiana, J., Antona, D., Javouhey, E., Madhi, F., Lorrot, M., Léger, P.-L., Galeotti, C., Claude, C., Wiedemann, A., et al. (2021) · JAMA · doi:10.1001/jama.2021.0694 · Cited by 354
Valverde, I., Singh, Y., Sanchez-de-Toledo, J., Theocharis, P., Chikermane, A., Di Filippo, S., Kuciñska, B., Mannarino, S., Tamariz-Martel, A., Gutierrez-Larraya, F., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050065 · Cited by 349
Harwood, R., Allin, B., Jones, C. E., Whittaker, E., Ramnarayan, P., Ramanan, A. V., Kaleem, M., Tulloh, R., Peters, M. J., Almond, S., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30304-7 · Cited by 336
SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities
Walensky, R. P., Walke, H. T., & Fauci, A. S. (2021) · JAMA · doi:10.1001/jama.2021.2294 · Cited by 319
Using Propensity Score Methods to Create Target Populations in Observational Clinical Research
Thomas, L., Li, F., & Pencina, M. (2020) · JAMA · doi:10.1001/jama.2019.21558 · Cited by 174
Jonat, B., Gorelik, M., Boneparth, A. D., Geneslaw, A. S., Zachariah, P., Shah, A. M., Broglie, L. A., Duran, J., Morel, K. D., Zorrilla, M. J. M., et al. (2020) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002598 · Cited by 148
Intravenous immunoglobulin for presumed viral myocarditis in children and adults
Robinson, J., Hartling, L., Vandermeer, B., & Klassen, T. P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004370.pub3 · Cited by 144
Belhadjer, Z., Auriau, J., Méot, M., Oualha, M., Renolleau, S., Houyel, L., & Bonnet, D. (2020) · Circulation · doi:10.1161/circulationaha.120.050147 · Cited by 101
Felsenstein, S., Willis, E., Lythgoe, H., McCann, L. J., Cleary, A. G., Mahmood, K., Porter, D., Jones, J., McDonagh, J. E. R., Chieng, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103293 · Cited by 82
Intravenous immunoglobulin for presumed viral myocarditis in children and adults
Robinson, J., Hartling, L., Vandermeer, B., Sebastianski, M., & Klassen, T. P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004370.pub4 · Cited by 64
Lin, M., Tseng, Y., Chen, M., Chung, C., Tsai, M.-H., Wang, P., Chang, J.-J., Chen, T., & Lin, Y. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0981-3 · Cited by 30
Cited by
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
A guide to immunotherapy for COVID-19
van de Veerdonk, F. L., Giamarellos-Bourboulis, E., Pickkers, P., Derde, L., Leavis, H., van Crevel, R., Engel, J. J., Wiersinga, W. J., Vlaar, A. P. J., Shankar-Hari, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01643-9 · Cited by 320
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Kernan, K. F., Schulert, G. S., Seo, P., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42062 · Cited by 296
Self-citationSARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
Husby, A., Hansen, J. V., Fosbøl, E., Thiesson, E. M., Madsen, M., Thomsen, R. W., Sørensen, H. T., Andersen, M., Wohlfahrt, J., Gislason, G., et al. (2021) · BMJ · doi:10.1136/bmj-2021-068665 · Cited by 275
Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant
Butt, A. A., Dargham, S. R., Loka, S., Shaik, R. M., Chemaitelly, H., Tang, P., Hasan, M. R., Coyle, P. V., Yassine, H. M., Al-Khatib, H. A., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac275 · Cited by 129
Metadata
- Authors
- Son, M. B. F., Murray, N., Friedman, K., Young, C. C., Newhams, M. M., Feldstein, L. R., Loftis, L. L., Tarquinio, K. M., Singh, A. R., Heidemann, S. M., Soma, V. L., Riggs, B. J., Fitzgerald, J. C., Kong, M., Doymaz, S., Giuliano, J. S., Keenaghan, M. A., Hume, J. R., Hobbs, C. V., Schuster, J. E., Clouser, K. N., Hall, M. W., Smith, L. S., Horwitz, S. M., Schwartz, S. P., Irby, K., Bradford, T. T., Maddux, A. B., Babbitt, C. J., Rowan, C. M., McLaughlin, G. E., Yager, P. H., Maamari, M., Mack, E. H., Carroll, C. L., Montgomery, V. L., Halasa, N. B., Cvijanovich, N. Z., Coates, B. M., Rose, C. E., Newburger, J. W., Patel, M. M., & Randolph, A. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07
- Volume
- 385
- Issue
- 1
- Pages
- 23-34
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3166141498
- Cited by
- 366
- References
- 28
- FWCI
- 68.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.